Biocon Ltd. reported a 95% fall in net profit for the first quarter of financial year 2026.
The pharma company reported a consolidated bottom line of Rs 31.4 crore, a sharp fall from net profit of Rs 659.70 crore in the year-ago period.
Biocon Q1 Highlights (Consolidated, YoY)
Revenue up 14.8% to Rs 3,941.90 crore versus Rs 3,432.90 crore.
Net profit down 95% to Rs 31.40 crore versus Rs 659.70 crore.
Ebitda up 21% to Rs 748.90 crore versus Rs 620.40 crore.
Margin at 19% versus 18.1%
WRITTEN BY
Add us to your Preferences
Set as your preferred source on Google
ADVERTISEMENT
RECOMMENDED FOR YOU

Net Direct Tax Collection Slips 4% In FY26 So Far, Refunds Rise 10%


FPIs Turn Net Sellers Despite Near 1% Rise In Nifty, Sensex

Axiscades Q1 Results: Profit Rises 24%


Bharti Airtel Q1 Results Preview: Net Profit, Revenue Expected To Rise; ARPU May Improve Marginally
